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Introduction: Patients undergoing cardiac surgery have an increased risk of postoperative pneumonia. Pulmonary
immune dysfunction might be a contributing factor. We therefore determined changes of the surface molecules on
alveolar macrophages (AMs). To characterize modulation in patients with pneumonia we correlated these changes
to the development of postoperative pneumonia.
Methods: After ethical approval and written informed consent, 33 patients undergoing elective coronary bypass
grafting surgery were included in this observational study. Peripheral blood cells and alveolar lavage fluid were
collected directly after induction of anesthesia and two hours after separation from cardiopulmonary bypass (CPB).
Human leukocyte antigen-DR (HLA-DR) and toll-like receptors (TLR) 2/4 expression on monocytes and AM were
assessed by flow cytometry. A total of three patients developed postoperative pneumonia determined according to
the criteria of the Center of Disease Control. Statistical analysis was performed with the Mann–Whitney-U test and
Wilcoxon test.
Results: We found significant changes of phenotypic and functional immune markers on AMs after cardiac surgery.
HLA-DR expression on peripheral blood monocytes and AMs was significantly reduced compared to baseline in all
patients (each approximately 30%). After surgery patients who developed postoperative pneumonia revealed a
trend of stronger reduction of HLA-DR expression (83.7% versus 27.1%) and TLR4 expression on AMs (46.1% versus
9.9%) compared to patients without pneumonia. Already before surgery, the baseline of TLR2 expression on AM
was significantly lower (27.7%) in patients who developed postoperative pneumonia.
Conclusions: As far as we know this is the first study that shows an early impairment of lung cellular immune
response after cardiac surgery. These findings can help to understand the role of cell-mediated immunosuppression
and its association to the development of postoperative pneumonia.Introduction
Patients undergoing cardiac surgery with cardiopulmonary
bypass (CPB) have a high risk for nosocomial infections
[1]. The most common infection is pneumonia (approxi-
mately 5 to 8%), causing a longer hospital stay and higher
mortality [2-4]. In particular, gram-negative bacteria, such
as Klebsiella pneumoniae, are common pathogens after* Correspondence: michael.sander@charite.de
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reproduction in any medium, provided the orcardiac surgery [4,5]. Perioperative dysregulation of the
pulmonary defense system may be associated with this fre-
quent complication [6-8].
Alveolar macrophages (AMs) are one of the major resi-
dent effector-cells of the pulmonary defense system against
respiratory tract pathogens. These local antigen-presenting
cells express human leukocyte antigen-DR (HLA-DR) pro-
tein, part of the major histocompatability complex (MHC)
class II system, that activates T lymphocytes and B cells
[9]. It has been shown that patients with decreased HLA-
DR levels (mHLA-DR) on circulating peripheral blood
monocytes have a higher risk for infections after surgerytd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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posed as a tool to predict the risk of secondary infection
[9]. Lukaszewicz et al. reported in a large study of 283 ICU
patients an association between persistent low mHLA-DR
expression and the development of nosocomial infections
[12]. Several immune-stimulating treatments (interferon γ
and granulocyte-macrophage colony-stimulating factor) in
septic patients could improve immune reactivity as indi-
cated by increasing mHLA-DR levels and monocytic cyto-
kine secretion [13,14]. A prospective clinical trial in 40
patients with septic neutropenic acute respiratory distress
syndrome (ARDS) suggests that decreased levels of HLA-
DR on AMs in the lung predispose to the development of
pulmonary infections [15]. These findings are supported
by a study of Muehlsted et al. who found a correlation
between the incidence of nosocomial pneumonia and a
prolonged reduction of HLA-DR expression on AMs in
injured patients [16].
Pathogens can be sensed by AM via toll-like receptors
(TLRs). Lipopolysaccharide (LPS), the major component
of gram-negative bacterial cell walls, activate AM
through the TLR4 receptor as a part of the LPS receptor
complex [17]. Other diverse bacterial elements, includ-
ing peptidoglycans from gram-positive bacteria, bind to
TLR2 [18]. Several experimental studies demonstrated
that TLR4 and TLR2 are crucial for the defense against
nosocomial pathogens including K. pneumoniae [19].
The binding of bacterial cell wall components to TLRs
on AMs results in the release of cytokines and chemo-
kines which induce the chemotaxis and activation of T
cells and neutrophils [20,21]. Hadley et al. showed a re-
duction of 29% of the TLR expression on monocytes at
the end of CPB. His workgroup was unable to link the
reduced cytokine production to the downregulation of
TLR expression but assumed that upregulation could
contribute to the recovery of the immune responsive-
ness [22].
Even though the systemic inflammatory response to
cardiac surgery with CPB is well-characterized [23-26],
the understanding of the local pulmonary effects re-
mains incomplete. We hypothesized that there is a sup-
pression of HLA-DR expression on AMs in patients
developing postoperative pneumonia compared to pa-
tients without this complication. Therefore, we tried to
characterize the effect of cardiac surgery with CPB on
early functional changes of AMs in this pilot observatory




After approval from the local ethics committee - the Ethics
Committee of the Charité - Universitätsmedizin Berlin
(EA1/192/05) - and informed written consent from 33patients undergoing elective coronary artery bypass graft-
ing (CABG), patients were enrolled in this prospective
clinical pilot trial. Inclusion criteria were age >18 years
and undergoing elective CABG surgery. Exclusion criteria
were missing signed informed consent, age <18 years,
pregnancy, lung disease with ambulatory oxygen respir-
ator, liver insufficiency (Child-Pugh classification > B),
HIV infection, corticosteroid therapy, status post organ
transplantation and preoperative signs of infection accord-
ing to the criteria of the Center of Disease Control,
Germany. Postoperative pneumonia was diagnosed with
the criteria of the Center of Disease Control.
Anesthetic, surgical course and intensive care
management
Patients were given etomidate, fentanyl and cis-atracurium
for induction and sevoflurane and fentanyl for mainten-
ance of the general anesthesia. An arterial catheter via the
left radial artery was used for measurement of arterial
blood pressure and to obtain blood samples for blood gas
analysis.
The standardized prime for the CBP circuit consisted
of 500 ml of crystalloid fluid and 500 ml of 10% hydro-
xyethylstarch solution. A total dose of 50,000 KIU aproti-
nin per kg bodyweight, 8,000 IE heparin, 250 ml mannitol
(20%) and 1 g methylprednisolone were administered dur-
ing CPB in all patients. All patients were monitored for at
least 24 hours at the ICU.
Sample extraction
Blood sampling
Arterial blood gas analyzes (BGA) and peripheral blood
samples (ethylenediaminetetraacetic acid (EDTA), heparin,
vacutainer, Becton Dickenson (BD), Heidelberg, Germany)
were taken before and after bronchoscopy prior to and
after surgery.
Bronchoalveolar lavage
After induction of anesthesia before surgery, and two
hours after separation from CPB we collected the bronchi-
olar lavage (BAL) fluid. Patients were ventilated with a
fraction of inspired oxygen of 1.0 during the intervention.
After placement of the bronchoscope in the wedge pos-
ition, 100 ml of saline solution (0.9%) was used preopera-
tively to aspirate cells from the right middle lobe and
postoperatively from the left lingula of the lung. The aspi-
rated fluid was filtered (cell strainer 100 μm, BD), centri-
fuged (10 minutes, 300 J) and the pellet resuspended in
culture medium (Roswell Park Memorial Institute medium
(RPMI), PAA Laboratory GmBH, Pasching, Austria). The
cells were counted in the counting chamber (Neubauer,
LO Laboroptic, Friedrichsdorfs, Germany) and adjusted to
a concentration of 5 × 106 cells per ml.
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For flow cytometry (FACS) analysis the following
fluorescence-labeled mouse anti-human monoclonal anti-
bodies (BD Biosciences; San Diego, CA, USA) were used:
cluster of differentiation (CD) 45 peridinin chlorophyll;
CD2, CD16 fluorescein isothiocyanate (FITC); CD3 and
CD19 phycoerythrin (PE); CD14 allophycocyanine (APC).
Briefly, 50 μl of EDTA blood or BAL cell suspension was
stained with fluorescently-labeled antibodies 30 minutes
in the dark at 4°C, washed and resuspended in PBS with
2% FCS. Samples were stored on ice until FACS analysis.
Cell phenotyping was performed by four-color flow
cytometry on a FACSCalibur™ using CELLQuest™ software
(BD Biosciences).
Surface markers on mononuclear cells
HLA-DR expression
For quantitative measurement of HLA-DR expression on
monocytes and AMs, 50 μl of blood or BAL cell suspen-
sion, respectively, was incubated with 20 μl QuantiBrite
Anti-HLA-DR PE/Anti-Monocyte PerCP-Cy5.5 (BD)
reagent for 30 minutes at room temperature. Blood sam-
ples were additionally incubated with 500 μl FACS lysing
solution (BD) for 15 minutes at room temperature for red
blood cell lysis. Cells were kept 4°C after washing, until
analysis by flow cytometry.
TLR2/4 expression
The measurement of TLR2/4 expression was performed
using two different AB mixes: For analysis of TLR2
expression a mix of CD45 peridinin chlorophyll, CD 14-
APC, (BD), TLR2-FITC and IgG2a-PE was used (BD
Biosciences). The TLR4 expression was measured with
CD45 peridinin chlorophyll, CD 14-APC, (BD), TLR4-
PE and IgG2a-FITC (BD Biosciences). Each mixture was
incubated with BAL cells (50 μl cells) for 30 minutes at
4°C and after one washing step was resuspended in buf-
fer solution (BD). Cells were stored on ice until the flow
cytometric measurements were performed.
Statistical methods
Owing to the limited sample sizes and asymmetrically
distributed observations we used nonparametric statis-
tical tests. Results are expressed as median and IQR for
continuous variables and percentage of frequencies for
categorical data: 95% confidence intervals were calcu-
lated. The data were analyzed with the non-parametric
Wilcoxon test for pairwise comparisons and the non-
parametric Mann Whitney U-test for independent groups
of patients. To calculate the relative changes (%) between
the groups the median values were used. P <0.05 was
considered statistically significant. Statistical analysis
was carried out using the Software Package for SocialSciences, 18.0 SPSS® for Windows® (SPSS, Inc., Chicago,
IL, USA).Results
Patients’ characteristics
Peripheral blood and BAL samples were obtained from
all 33 patients. The baseline characteristics are given
in Table 1. Retrospectively the patients were divided
into group 1 (those without postoperative pneumonia,
n = 30) and group 2 (those with postoperative pneumonia,
n = 3).
The patients in group 2 all had arterial hypertension
and one patient had renal insufficiency and diabetes melli-
tus. They were all non-smokers and had no chronic
obstructive pulmonary disease (COPD). All patients with
postoperative pneumonia had prolonged CPB and ventila-
tion times and received intraoperative blood transfusions.
Two patients with postoperative pneumonia developed se-
vere sepsis, died within 60 days. The demographic data
were similar in all patients. In group 2 the patients were
significantly older and had significantly longer duration of
surgery and CPB. Relevant pre-existing medical conditions
were mainly arterial hypertension, and in a small patient
group there was also COPD, renal insufficiency and dia-
betes mellitus.
Ten patients received blood products during surgery.
Seven patients developed postoperative infection: four
developed wound infection and three developed postop-
erative pneumonia. The incidence of postoperative pneu-
monia was 9%. The median of the onset of pneumonia
was on postoperative day (POD) 5. Two of the patients
with postoperative pneumonia developed septic shock
and lethal severe sepsis whilst in the ICU.Cell counts and differential staining
The systemic leukocyte counts were within normal
range before surgery: 7.3/μL (6.2/μL to 8.8/μL) and were
significantly elevated after surgery 10.3/μL (9.2/μL to
13.8/μL) (P = 0.001) and on the first POD 12.8/μL (11.5/μL
to 14.2/μL) (P = 0.001) compared to preoperative values.
The peripheral blood samples showed significant changes
in the differential subsets with a reduced percentage of
monocytes and lymphocytes after surgery for all patients.
Neutrophil counts were significantly higher compared
to preoperative samples for all patients (data given in
Table 2).
BAL samples showed similar differential subsets before
and after surgery. The percentage of AMs after surgery
was reduced by trend in group 1 (P = 0.06). In patients
with postoperative pneumonia (group 2) AMs showed a
strong reduction after surgery (P = n/a) (data given in
Table 2).
Table 1 Baseline characteristics of the analyzed patient groups
Characteristics Group 1 without pneumonia (n = 30) Group 2 with pneumonia (n = 3) P
Age, years 67 (59, 72) 79 (78, 84) 0.006a
Gender, m/f 22 (73%)/8 (27%) 2 (66%)/1 (33%) 0.88
Smoker, % 3 (10%) 0 (0%) 0.49
BMI, kg m-2 27.5 (25.5, 29.7) 26.9 (22.5, 28.03) 0.45
LVEF, % 55 (50, 60) 55 (50, 66) 0.75
Arterial hypertension, n/y 2/31 0/3 0.88
COPD, n/y 31/2 3/0 0.88
Renal insufficiency, % 2 (6.7%) 1 (33%) 0.49
Diabetes mellitus, % 6 (20%) 1 (33%) 0.75
Duration of anesthesia, minutes 270 (234, 318) 360 (330, 360) 0.019a
Duration of surgery, minutes 213 (173, 244) 275 (275, 320) 0.025a
CPB-time, minutes 73 (54, 99) 125 (101, 142) 0.030 a
Cross clamp time, minutes 41 (32, 61) 58 (40, 97) 0.235
Total ventilation time, hours 13 (11.0, 15) 24 (22, 25) 0.015a
Intraoperative blood transfusion, n/y 7 (23%) 3 (100%) 0.025a
Postoperativewound infection, % 4 (13.3%) 0 (0%) 0.75
Onset of pneumonia, postoperative day n/a 5 (4, 5) 0.10
Sepsis, % 0 (0%) 2 (67%) 0.06
Data in brackets are presented as median and IQR or absolute values. aStatistically significant (P <0.05) (Mann–Whitney U-test for independent patient groups).
Patients were divided retrospectively into two groups: group 1 without postoperative pneumonia and group 2 comprising three patients who developed
postoperative pneumonia. m/f, male/female; n/y, no/yes; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass;
n/a, not applicable.
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HLA-DR expression on peripheral blood monocytes (n = 31)
was significantly diminished after surgery in the whole pa-
tient population (P = 0.001). In patient group 1 mHLA-DR
expression went down significantly (P = 0.001). In group 2
mHLA-DR was also strongly reduced by trend (P = n/a).Table 2 Differential subsets of peripheral blood and broncho
Peripheral blood subsets (%)
Time point Preoperative Postoperative
Macrophages (n = 33) n/a n/a
Group 1 (n = 30) n/a n/a
Group 2 (n = 3) n/a n/a
Monocytes (n = 33) 8.0 (6.7, 9.9) 4.0 (2.6, 5.7)
Group 1 (n = 30) 7.9 (6.7, 10.2) 4.4 (2.8, 6.0)
Group 2 (n = 3) 9.3 (7.1, 9.6) 2.3 (2.2, 4.0)
Lymphocytes (n = 33) 21.4 (17.1, 30.3) 7.4 (5.8, 11.9)
Group 1 (n = 30) 21.6 (17.5, 29.7) 7.5 (5.7, 11.7)
Group 2 (n = 3) 6.4 (5.8, 34.4) 6.9 (6.2, 10.2)
Neutrophils (n = 33) 66.7 (57.7, 74.3) 87.4 (81.4, 91.2)
Group 1 (n = 30) 66.6 (57.8, 74.0) 87.2 (80.4, 91.3)
Group 2 (n = 3) 82.4 (56.6, 83.5) 88.9 (87.4, 91.3)
In the peripheral blood samples (n = 33) the monocytes and lymphocytes were sign
elevated. The findings in the bronchiolar lavage samples (n = 33) were different. Th
macrophages was significantly reduced after surgery. Data are given as medians an
difference for the dependent variables; asignificantly different; n/a, not available.Comparing the two groups (1 vs. 2) mHLA-DR expres-
sions did not differ before (P = 0.97) or after surgery
(P = 0.12) (data given in Table 3).
HLA-DR expression on AMs (n = 31) was also signifi-
cantly reduced after surgery in the whole patient popula-
tion (P = 0.001). Group 1 was significantly diminishedalveolar lavage samples
Bronchoalveolar subsets (%)
P Preoperative Postoperative P
63.5 (38.8, 76.5) 52.2 (21.5, 69.6) 0.018a
63.2 (35.2, 73.0) 53.4 (22.0, 70.2) 0.06
77.1 (56.7, 85.7) 27.9 (7.5, 57.4) n/a
0.001a 3.4 (2.3, 4.6) 3.1 (1.8, 4.7) 0.83
0.001a 3.3 (2.3, 4.2) 3.2 (2.0, 4.7) 0.758
n/a 4.3 (2.4, 11.9) 1.8 (1.7, 7.5) n/a
0.001a 11.4 (7.4, 14.5) 9.2 (4.6, 17.1) 0.99
0.001a 11.5 (7.7, 15.7) 9.9 (5.7, 19.2) 0.673
n/a 13.1 (4.7, 14.2) 4.3 (3.4, 11.4) n/a
0.001a 10.6 (3.1, 28.8) 15.1 (2.1, 46.7) 0.088
0.001a 11.3 (3.1, 35.5) 14.3 (1.8, 41.0) 0.254
n/a 4.8 (3.1, 11.7) 45.2 (15.1, 82.7) n/a
ificantly reduced after surgery, whereas the neutrophils were significantly
e trend was similar to the blood samples but only the percentage of
d IQR in brackets. The Wilcoxon test was used to calculate significant
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applicable (n/a)) (Figure 1).
Comparing the two groups (1 versus 2), in group 2 the
baseline HLA-DR expression was lower by trend (P = 0.20)
and the postoperative values were significantly reduced
(P = 0.024).
TLR2/4 expression on AMs
We found no significant changes of TLR2/4 expression
on AMs after surgery in the whole patient population
(n = 32): for TLR2 P = 0.31, and for TLR4 P = 0.77 (data
given in Table 4).
The TLR2 expression in group 1 (P = 0.32) and group
2 (P = n/a) was not different before and after surgery
(Figure 2). TLR4 expression in group 1 showed similar re-
sults before surgery and after surgery (P = 0.15) (Figure 3).
In group 2 the TLR4 the expression was reduced by trend
after surgery (P = n/a) (Figure 3).
Interestingly, comparing the two groups (1 versus 2)
we found a significantly lower baseline TLR2 (P = 0.027)
in group 2, whereas the baseline TLR4 did not differ
(P = 0.45). However, postoperatively in group 2 the TLR4
expression was significantly reduced (P = 0.041) addition-
ally to the trend for lower TLR2 expression (P = 0.21).
Discussion
Our results show significant changes in phenotypic and
functional immune markers on AMs early after cardiac
surgery. In addition to the well-known systemic immune
impairment there seems to be a pulmonary immuno-
suppression characterized by a diminished HLA-DR ex-
pression on AM after surgery. The three patients with
postoperative pneumonia (9%) were characterized pre-
operatively by a lower baseline HLA-DR (−35.4%) and
TLR2 expression (−27.7%). After surgery the expression
of HLA-DR (−83.7%), as well as the TLR4 expression
(−46.1%), was significantly reduced.
Cardiac surgery poses a high risk for the development of
postoperative pneumonia, causing high morbidity and
mortality in these patients [1-4]. The early identification
of patients at risk for the development of postoperative
pneumonia would be desirable, however is still difficult.
In recent years various attempts have been made to findTable 3 HLA-DR expression (antibody/cell) on peripheral bloo
Peripheral blood monocytes
Time point Preoperative Postoperative p
All (n = 31) 26,587 (20,410, 31,478) 13,996 (11,724, 17,706) 0.001
Group 1 (n = 28) 26,266 (20,646, 31,415) 15,258 (12,365, 18,580) 0.001
Group 2 (n = 3) 27,882 (12,325, 34,088) 10,292 (10,288, 13,389) n/a
HLA-DR expression on peripheral blood monocytes as well as on AMs was significa
significance was seen. Data are given as medians and IQR in brackets. The Wilcoxon
astatistically significant difference. HLA-DR, human leukocyte antigen-DR; AM, alveomarkers and risk factors to predict the development of
nosocomial pneumonia after cardiac surgery. A large
cohort study in the USA in 17,145 patients undergoing
cardiac surgery was performed to clarify the derivation
and validation of postoperative pneumonia [27]. In this
study only 361 patients (2%) developed pneumonia.
They were able to identify thirteen independent predic-
tors for postoperative pneumonia, for example body
mass index <18.5, smoking history, creatinine level over
1.2 mg/dl, blood transfusion, mechanical ventilation
time >24 hours, cancer history and emergency status.
The authors concluded that it may be useful to prove
the concept of preventive interventions [27]. However,
specificity of this risk model seems to be poor and pre-
vents implementation of preventive strategies. Another
cohort study from Brazil in 331 patients with a rate of
16% for postoperative pneumonia comes to the conclusion
that preoperative level of highly sensitive C-reactive pro-
tein (CRP) >3 mg/l is an independent predictor for post-
operative respiratory infection [28]. However, specificity is
also problematic with this approach, as CRP is not only
increased in pulmonary infections, but also in a variety of
comorbidities. The key to understanding postoperative
pulmonary infection might be the local host-response to
pathogens and the resulting pattern of immune markers.
This might help to obtain insights into the immune re-
sponse after surgery and the associated change with
localized infections.
Muehlstedt et al. showed a correlation between low
HLA-DR levels on AMs and pneumonia in injured pa-
tients. The authors demonstrated that the reduced HLA-
DR expression on AMs preceded nosocomial pneumonia
and they suggested that a local immune suppression of
the lung with altered effector cell function could be re-
sponsible [16]. In their setting they compared patients
12 hours after injury, to a control group of healthy volun-
teers. Six of sixteen patients developed nosocomial pneu-
monia and had persistent low HLA-DR expression on
AMs, whereas in the patients without pneumonia the
HLA-DR expression returned to normal 60 hours after in-
jury [16]. In our patient group the population of AMs was
reduced 2 hours after separation from CBP with a signifi-
cantly lower ability to express HLA-DR in patients whod monocytes and AMs
AMs
Preoperative Postoperative P
a 985,234 (698,683, 1,293,531) 712,564 (320,726, 941,120) 0.001a
a 1,009,337 (739,280, 1,294,545) 736,306 (430,604, 943,491) 0.002a
652,262 (505,628, 985,234) 106,139 (42,434, 417,111) n/a
ntly reduced after surgery. In group 2 a strong reduction without statistical












Figure 1 Human leukocyte antigen-DR (HLA-DR) expression on
alveolar macrophages (AMs). HLA-DR expression on AM in group 1
(n = 28) showed a significant reduction after surgery (P= 0.002). In group
2 (n = 3), HLA-DR expression was highly diminished after surgery not
possible to calculate P value with only 3 patients. Comparing both groups
the baseline had a tendency to be lower (P= 0.20) and the postoperative
HLA-DR expression was significantly reduced in group 2 (P= 0.024). Box
plots represent median and IQR; blue, values before surgery; green, values
after surgery. The Wilcoxon test was used for dependent groups and the
Mann–Whitney U-test for independent groups; *P <0.05.
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that AM function is compromised already at this early
time point. Unfortunately we were not able to examine
the pulmonary immune function at a later time point as it
was unethical to prolong the ventilation time longer than
necessary. Since the onset of pneumonia was on day five,
it might be possible that the function of AMs remains re-
duced for several days. This possible explanation needs to
be addressed in further investigations.
In agreement with other studies our data show that pa-
tients after cardiac surgery with CPB have strong systemic
immune depression [23,24,26]. The peripheral blood sub-
sets were altered with significant reduction of monocytes
and lymphocytes, and significantly higher neutrophil popu-
lations after surgery. In addition, mHLA-DR expression
was significantly reduced after surgery. Large clinical
trials have already suggested that persisting low levels of
mHLA-DR expression could be used as an usefulTable 4 TLR2/4 expression (antibody/cell) on AMs
TLR2
Time point Preoperative Postoperative
All (n = 32) 55.2 (46.0, 81.9) 52.1 (41.2, 72.0)
Group 1 (n = 29) 59.3 (51.0, 84.5) 52.2 (41.4, 76.1)
Group 2 (n = 3) 42.9 (34.6, 43.0) 30.0 (22.1, 58.1)
TLR2 and TLR4 levels did not differ before and after surgery. In group 2 the TLR4 le
and IQR in brackets. The Wilcoxon test was used to calculate significant difference fbiomarker for the development of nosocomial infection
in ICU patients [9,12].
Assessment of monocytic HLA-DR expression as an
indicator for patients at risk for postoperative pneumo-
nia is relatively easy to implement in clinical routine
diagnostics. In this study, we also observed reduced
HLA-DR levels on monocytes at 2 hours after surgery
with a reduction of median values of 33.6% compared to
baseline. However, our results failed to show significant
differences between patients who did or did not develop
pneumonia at this early point, likely due to the small
sample size. Therefore, the hypothesis that the early
local immunosuppression in the lung could be associ-
ated with higher susceptibility to developing postopera-
tive pneumonia needs further investigation.
Additionally, in patients who developed postoperative
pneumonia, we found significantly lower TLR2 levels
on AMs even before surgery. One possible hypothesis
is that this might be a sign of prevalence of bacterial
colonization of the respiratory tract. In the current lit-
erature we found no data about the prevalence of air-
way bacterial colonization in healthy patients, but in
stable COPD patients a colonization rate of over 50%
has been seen [29,30]. Possibly, the strong surgical stress
with mechanical ventilation permits pathogens colonizing
the respiratory tract to proliferate. Unfortunately we did
not take microbiological samples in this study. However,
we are planning to investigate this aspect in further
studies.
After surgery the TLR4 levels were significantly reduced
on AMs. These findings might contribute to development
of postoperative pneumonia, as other trials have been able
to link the importance of TLR4 expression to the risk of
pneumonia [19,31]. A small clinical study in six patients
undergoing cardiac surgery described a reduction of sys-
temic TLR2/4 expression on monocytes after surgery
down to 29% that recovered up to 120% on the first post-
operative day, indicating that receptor upregulation is a
sign of recovery of responsiveness [22]. Unfortunately the
incidence of postoperative infection was not part of this
study. In contrast to the aforementioned study in our
study design only early changes were analyzed. A recovery
of the TLR4 expression on AMs on the first postoperative
day might also be possible in our patient population.TLR4
P Preoperative Postoperative P
0.31 63.6 (48.4, 94.1) 57.0 (41.7, 87.4) 0.77
0.32 64.6 (48.9, 97.9) 58.2 (43.7, 89.8) 0.15
n/a 62.7 (36.4, 75.2) 33.8 (33.8, 36.1) n/a
vels were strongly reduced by trend after surgery. Data are given as medians












Figure 3 Toll-like receptor (TLR)4 expression on alveolar
macrophages (AMs). The TLR4 expression did not differ before or
after surgery in group 1 (n = 29) (P = 0.15). In group 2 (n = 3), TLR4
expression tended to be reduced (P not applicable (n/a)). Comparing
the groups the baseline of TLR4 did not differ (P = 0.45). However,
after surgery the TLR4 expression was significantly diminished in
group 2 (P = 0.041). Box plots represent median and IQR; blue, values
before surgery; green, values after surgery. The Wilcoxon test was used

















Figure 2 Toll-like receptor (TLR)2 expression on alveolar
macrophages (AMs). TLR2 expression in group 1 (n = 29) did not
differ before and after surgery (P = 0.32). In group 2 (n = 3) the TLR2
expression was lower by trend after surgery not possible to calculate
P value with 3 patients (as in Figure 1 and 3). Comparing both groups,
group 2 showed a significantly lower baseline of TLR2 expression
(P = 0.027) and a tendency of lower postoperative values (P = 0.21). Box
plots represent median and IQR; blue, values before surgery; green,
values after surgery. The Wilcoxon test was used for dependent groups
and the Mann–Whitney U-Test for independent groups; *P <0.05.
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for HLA-DR and TLR levels to healthy controls. How-
ever, in the literature to our best knowledge no such
data have so far been published.Limitations
The major limitation of this study is the small group of pa-
tients who developed postoperative pneumonia. As this
study was designed as a pilot study we were unable to in-
clude more patients at the time, however, we are planning
a large interventional trial to verify our important findings.
We cannot exclude activation of the AMs by the initial
BAL in the right lobe before surgery. However, we tried to
minimize these effects by performing the postoperative
BAL in the left lobe. Furthermore, there might have been
activation of the cells due to the laboratory protocol.
However, as this was a clinical study in patients where all
samples were treated equally, these manipulations could
be disregarded as a confounding factor to our reported re-
sults. A multiplicity of factors such as age, gender, ventila-
tion time, application of methylprednisolone and the use
of blood products influence the perioperative immune
function. Patients in group 2 were significantly older and
had longer duration of surgery. These factors could also
influence the levels of HLA-DR and TLR expression.Unfortunately, this pilot study has not the statistical power
to identify or validate risk factors.
Conclusions
Our results indicate that besides the systemic immune
impairment after surgery an even stronger local im-
munosuppression in the lung might be a risk factor for
pulmonary infections after cardiac surgery. Patients who
developed pneumonia in this study showed a significant
postoperative reduction of HLA-DR expression on AMs.
This might indicate that concomitant to systemic immune
dysfunction there is local dysregulation of the pulmonary
compartment. These findings support the hypothesis of
local cell-mediated immunosuppression and its associ-
ation with the development of postoperative pneumonia.
Further research needs to be performed to confirm the re-
sults from our group and others, and to put this into con-
text of preventive measures.
Key messages
 Alveolar macrophages are reduced after cardiac
surgery
Chalk et al. Critical Care 2013, 17:R285 Page 8 of 9
http://ccforum.com/content/17/6/R285 Systemic and localized cell-mediated immune func-
tion is impaired after cardiac surgery
 Pronounced pulmonary cell-mediated immmunosup-
pression after cardiac surgery precedes pneumonia.
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